A new prospect in cancer therapy: Targeting cancer stem cells to eradicate cancer

Chinese Journal of Cancer

Volumn 31, Issue 12, 2012, Pages 564-572

  Chen, Li Sha ^a,b,c   Wang, An Xin ^a,b,c   Dong, Bing ^a,b,c   Pu, Ke Feng ^a,b,c   Yuan, Li Hua ^a   Zhu, Yi Min ^a  

^a SUZHOU INSTITUTE OF NANO TECH AND NANO BIONICS   (China)

^b INSTITUTE OF BIOPHYSICS   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Cancer stem cells; Pharmaceutical carriers; Targeting therapy

Indexed keywords

ABC TRANSPORTER; BETA CATENIN; BIOLOGICAL MARKER; CD133 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; ENDOGLIN; FLUORESCENT DYE; GOLD NANOPARTICLE; HERMES ANTIGEN; NANOCARRIER; SILVER NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; WNT PROTEIN;

ARTICLE; CANCER CONTROL; CANCER RECURRENCE; CANCER STEM CELL; CANCER STEM CELL THEORY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL LABELING; CELL PROLIFERATION; CELL SURFACE; DRUG SENSITIZATION; GENE SILENCING; GENE TARGETING; HUMAN; IN VIVO STUDY; INTRACELLULAR SIGNALING; MEDICAL HISTORY; MOLECULARLY TARGETED THERAPY; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES CONCERNING CELLS; STEM CELL NICHE DESTRUCTION; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; DRUG CARRIERS; GOLD; HUMANS; NANOSTRUCTURES; NEOPLASMS; NEOPLASTIC STEM CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871142437     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.011.10444     Document Type: Article

References (72)

1. Bomken S, Fišer K, Heidenreich O, et al. Understanding the cancer stem cell. Br J Cancer, 2010,103:439-445.
2. Shackleton M, Quintana E, Fearon ER, et al. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell, 2009,138:822-829.
3. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer, 2008,8:755-768.
4. Dick JE. Breast cancer stem cells revealed. P Natl Acad Sci USA, 2003,100:3547-3549.
5. Hewitt HB. Studies of the quantitative transplantation of mouse sarcoma. Br J Cancer, 1953,7:367-383.
6. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med, 1997,3:730-737.
7. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med, 2006,355:1253-1261.
8. Deonarain MP, Kousparou CA, Epenetos AA. Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? MAbs, 2009,1:12-25.
9. Tang C, Ang BT, Pervaiz S. Cancer stem cell: target for anti-cancer therapy. FASEB J, 2007,21:3777-3785.
10. Schatton T, Frank NY, Frank MH. Identification and targeting of cancer stem cells. Bioessays, 2009,31:1038-1049.
11. Eramo A, Haas TL, De Maria R. Lung cancer stem cells: tools and targets to fight lung cancer. Oncogene, 2010,29:4625-4635.
12. Yang YM, Chang JW. Bladder cancer initiating cells (BCICs) are among EMA(-)CD44v6(+) subset: novel methods for isolating undetermined cancer stem (initiating) cells. Cancer Invest, 2008,26:725-733.
13. Wakamatsu Y, Sakamoto N, Oo HZ, et al. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathol Int, 2012,62:112-119.
14. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature, 2008,451:345-U311.
15. Chiba T, Kita K, Zheng YW, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology, 2006,44(1):240-251.
16. Gilbert CA, Ross AH. Cancer stem cells: cell culture, markers, and targets for new therapies. J Cell Biochem, 2009,108:1031-1038.
17. Sell S. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol, 2004,51:1-28.
18. Bao SD, Wu QL, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res, 2006,66:7843-7848.
19. Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell, 2009,138(4):645-659.
20. Goodell MA, Brose K, Paradis G, et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med, 1996,183:1797-1806.
21. Ho MM, Ng AV, Lam S, et al. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res, 2007,67:4827-4833.
22. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA, 2004,101:14228-14233.
23. Hadnagy A, Gaboury L, Beaulieu R, et al. SP analysis may be used to identify cancer stem cell populations. Exp Cell Res, 2006,312:3701-3710.
24. Li HZ, Yi TB, Wu ZY. Suspension culture combined with chemotherapeutic agents for sorting of breast cancer stem cells. BMC Cancer, 2008,8:135.
25. Yu SC, Bian XW. Enrichment of cancer stem cells based on heterogeneity of invasiveness. Stem Cell Rev Rep, 2009,566-71.
26. Louie E, Nik S, Chen JS, et al. Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. Breast Cancer Res, 2010,12:R94.
27. Winquist RJ, Furey BF, Boucher DM. Cancer stem cells as the relevant biomass for drug discovery. Curr Opin Pharmacol, 2010,10:385-390.
28. Zhang J, Campbell RE, Ting AY, et al. Creating new fluorescent probes for cell biology. Nat Rev Mol Cell Biol, 2002,3:906-918.
29. Frankland-Searby S, Bhaumik SR. The 26S proteasome complex: an attractive target for cancer therapy. Biochim Biophys Acta, 2012,1825:64-76.
30. Pan J, Zhang Q, Wang YA, et al. 26S proteasome activity is down-regulated in lung cancer stem-like cells propagated in vitro. PLoS One, 2010,5:e13298.
31. Ge F, Xiao CL, Bi LJ, et al. Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells. PLoS One, 2010,5:e13095.
32. Vlashi E, Kim K, Lagadec C, et al. In vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst, 2009,101:350-359.
33. Alivisatos AP, Gu WW, Larabell C. Quantum dots as cellular probes. Annu Rev Biomed Eng, 2005,7:55-76.
34. Parak WJ, Pellegrino T, Plank C. Labelling of cells with quantum dots. Nanotechnology, 2005,16:R9-R25.
35. Jasmin, Torres ALM, Nunes HMP, et al. Optimized labeling of bone marrow mesenchymal cells with superparamagnetic iron oxide nanoparticles and in vivo visualization by magnetic resonance imaging. J Nanobiotechnol, 2011,9:4.
36. Arbab AS, Jordan EK, Wilson LB, et al. In vivo trafficking and targeted delivery of magnetically. Hum Gene Ther, 2004,15: 351-360.
37. Lewin M, Carlesso N, Tung CH, et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol, 2000,18:410-414.
38. Lee J, Yang J, Ko H, et al. Multifunctional magnetic gold nanocomposites: human epithelial cancer detection via magnetic resonance imaging and localized synchronous therapy. Adv Funct Mater, 2008,18:258-264.
39. Jin LQ, Hope KJ, Zhai QL, et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med, 2006,12: 1167-1174.
40. Wang Y, Krivtsov AV, Sinha AU, et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science, 2010,327:1650-1653.
41. Vilimas T, Mascarenhas J, Palomero T, et al. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med, 2007,13:70-77.
42. Qiang L, Wu T, Zhang HW, et al. HIF-1alpha is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway. Cell Death Differ, 2012,19: 284-294.
43. Steg AD, Bevis KS, Katre AA, et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res, 2012,18:869-881.
44. Kim Y, Kim KH, Lee J, et al. Wnt activation is implicated in glioblastoma radioresistance. Lab Invest, 2012,92:466-473.
45. Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol, 2009,14:3-9.
46. Ding XW, Wu JH, Jiang CP. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci, 2010,86:631-637.
47. Gatti L, Cossa G, Beretta GL, et al. Novel insights into targeting ATP-binding cassette transporters for antitumor therapy. Curr Med Chem, 2011,18:4237-4249.
48. Moitra K, Lou H, Dean M. Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther, 2011,89:491-502.
49. McCord AM, Jamal M, Williams ES, et al. CD133(+) glioblas-toma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. Clin Cancer Res, 2009,15:5145-5153.
50. Johannessen TCA, Bjerkvig R, Tysnes BB. DNA repair and cancer stem-like cells-potential partners in glioma drug resistance. Cancer Treat Rev, 2008,34:558-567.
51. Costello RT, Mallet F, Gaugler B, et al. Human acute myeloid leukemia CD34 (+)/CD38 (-) progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res, 2000,60:4403-4411.
52. Garvalov BK, Acker T. Cancer stem cells: a new framework for the design of tumor therapies. J Mol Med, 2011,89:95-107.
53. Pham PV, Phan NLC, Nguyen NT, et al. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. J Transl Med, 2011,9: 209.
54. Lou H, Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene, 2007,26: 1357-1360.
55. Gu W, Yeo E, McMillan N, et al. Silencing oncogene expression in cervical cancer stem-like cells inhibits their cell growth and self-renewal ability. Cancer Gene Ther, 2011,18: 897-905.
56. Binello E, Germano IM. Targeting glioma stem cells: a novel framework for brain tumors. Cancer Sci, 2011,102:1958-1966.
57. Folkins C, Man S, Xu P, et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res, 2007,67:3560-3564.
58. Luk SU, Yap WN, Chiu YT, et al. Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population. Int J Cancer, 2011,128:2182-2191.
59. Luk SU, Lee TKW, Liu J, et al. Chemopreventive effect of PSP through targeting of prostate cancer stem cell-like population. PLoS One, 2011,6: e19804.
60. Singh R, Lillard Jr JW. Nanoparticle-based targeted drug delivery. Exp Mol Pathol, 2009,86:215-223.
61. Faraji AH, Wipf P. Nanoparticles in cellular drug delivery. Bioorg Med Chem, 2009,17:2950-2962.
62. Lewinski N, Colvin V, Drezek R. Cytotoxicity of nanoparticles. Small, 2008,4:26-49.
63. Wang LM, Liu Y, Li W, et al. Selective targeting of gold nanorods at the mitochondria of cancer cells: implications for cancer therapy. Nano Lett, 2011,11:772-780.
64. AshaRani PV, Low Kah Mun G, Hande MP, et al. Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS Nano, 2009,3:279-290.
65. Zhang L, Xia J, Zhao Q, et al. Functional graphene oxide as a nanocarrier for controlled loading and targeted delivery of mixed anticancer drugs. Small, 2010,6:537-544.
66. Wang CH, Chiou SH, Chou CP, et al. Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody. Nanomedicine, 2011,7:69-79.
67. Cheng J, Teply B, Sherifi I, et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials, 2007,28:869-876.
68. + cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell, 2010,6:603-615.
69. Zhu Z, Hao XF, Yan MX, et al. Cancer stem/progenitor cells are highly enriched in CD133(+)CD44 (+) population in hepatocellular carcinoma. Int J Cancer, 2010,126:2067-2078.
70. Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastro-enterology, 2007,132:2542-2556.
71. Yamashita T, Ji JF, Budhu A, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology, 2009,136: 1012-1024.
72. Takaishi S, Okumura T, Tu SP, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells, 2009,27:1006-1020.